Annual Meeting, researchers presented risk-adjusted findings that shed new light on treatments for severe emphysema.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

Announcement of the 15 medicines chosen for the second round of negotiations was one of the Biden administration’s final ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

The Swiss drug development company Windward Bio ... such as boosting inflammation in asthma and COPD. WIN378 is not the first ...

REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.